Xilio Q1 net loss $17.2M; Gilead deal funds cash runway into Q2 2025

Xilio Therapeutics, Inc.

2024-Q1 EPS reported -$0.62

Net loss $17.2M in Q1 2024 vs $22.6M YoY; cash and equivalents $34.0M at March 31.
In April 2024 received $30M upfront + $13.5M equity from Gilead; up to $592.5M in potential milestones.
Plan to initiate Phase 2 trial for XTX101 (anti-CTLA-4) in MSS CRC in Q3 2024; data in Q4 2024.
Discontinued XTX202 monotherapy; exploring combo development opportunities.
Cash runway expected into Q2 2025, including $44.6M in April gross proceeds from Gilead and private placements.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xilio Therapeutics, Inc. reported financial results for quarter ended March 31, 2024.

Period: quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 and other business highlights.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-008063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.